BRIEF COMMUNICATION: COMMENTARY ON PREVENTION A POSSIBLE DRUG–DRUG INTERACTION: IS CONCURRENT ADMINISTRATION OF ORLISTAT AND PIOGLITAZONE INCREASE THE RISK OF DURG‑INDUCED HEPATOTOXICITY?

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

EMZHIK MARJAN; RAHIMI MOGHADDAM PARVANEH; EBRAHIMI SOLTAN AHMAD; KEYHANFAR FARIBORZ; MOAZZAM ASHRAF ALSADAT

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: International Journal of Preventive Medicine Year:2015 | Volume:6 | Issue:2 Page(s): 0-0

Download Full-Text

View:

381

Download:

203

Cites:

Information Journal Paper

Title

BRIEF COMMUNICATION: COMMENTARY ON PREVENTION A POSSIBLE DRUG–DRUG INTERACTION: IS CONCURRENT ADMINISTRATION OF ORLISTAT AND PIOGLITAZONE INCREASE THE RISK OF DURG‑INDUCED HEPATOTOXICITY?

Author(s)

Keywords

DRUG‑DRUG INTERACTION

HUMAN HEPATOCELLULAR CARCINOMA CELLS

LIVER TOXICITY

ORLISTAT

PIOGLITAZONE

Abstract

Background: Drug–drug interactions (DDIs) are an emerging threat to public health and are difficult to detect. To prevent DDIs and their burden, the possible DDIs should be kept in mind. We know that the obesity predisposes to the development of insulin resistance and type 2 diabetes. Therefore, combinational uses of antiobesity drugs and glucose‑lowering drugs are very common. As the hepatotoxicity of both PIOGLITAZONE (an antidiabetic drug) and ORLISTAT (an antiobesity drug) has been shown in some cases, the aim of this study was to evaluate the interaction of PIOGLITAZONE and ORLISTAT in human hepatocellular cell line human hepatocellular carcinoma (HepG2) cells to determine their effect on LIVER TOXICITY.Methods: HUMAN HEPATOCELLULAR CARCINOMA CELLS were treated with 25 mM Pioglitazon (Pio), 20 mM ORLISTAT (Orl) PIOGLITAZONE, ORLISTAT or combination of them. The MTT assay was used to assess cell viability.Results: PIOGLITAZONE and ORLISTAT combination caused a loss of HepG2 cell viability. While PIOGLITAZONE (25 mM) and orliatat (20 mM) alone decreased the cell viability around 91% and 85% respectively (notsignificant, P>0.05), the combination of these two drugs reduced the amount of viable cells to 55% which was significant when compared with each drug alone (P<0.001).Conclusions: Revealing the significant loss of viability of HepG2 cells in the combination use of PIOGLITAZONE and ORLISTAT indicates these two drugs should not be administered at the same time to prevent their hepatotoxic effects especially in patients with liver dysfunction.

Cites

No record.

References

No record.

Cite

APA: Copy

EMZHIK, MARJAN, RAHIMI MOGHADDAM, PARVANEH, EBRAHIMI, SOLTAN AHMAD, KEYHANFAR, FARIBORZ, & MOAZZAM, ASHRAF ALSADAT. (2015). BRIEF COMMUNICATION: COMMENTARY ON PREVENTION A POSSIBLE DRUG–DRUG INTERACTION: IS CONCURRENT ADMINISTRATION OF ORLISTAT AND PIOGLITAZONE INCREASE THE RISK OF DURG?INDUCED HEPATOTOXICITY?. INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 6(2), 0-0. SID. https://sid.ir/paper/316275/en

Vancouver: Copy

EMZHIK MARJAN, RAHIMI MOGHADDAM PARVANEH, EBRAHIMI SOLTAN AHMAD, KEYHANFAR FARIBORZ, MOAZZAM ASHRAF ALSADAT. BRIEF COMMUNICATION: COMMENTARY ON PREVENTION A POSSIBLE DRUG–DRUG INTERACTION: IS CONCURRENT ADMINISTRATION OF ORLISTAT AND PIOGLITAZONE INCREASE THE RISK OF DURG?INDUCED HEPATOTOXICITY?. INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE[Internet]. 2015;6(2):0-0. Available from: https://sid.ir/paper/316275/en

IEEE: Copy

MARJAN EMZHIK, PARVANEH RAHIMI MOGHADDAM, SOLTAN AHMAD EBRAHIMI, FARIBORZ KEYHANFAR, and ASHRAF ALSADAT MOAZZAM, “BRIEF COMMUNICATION: COMMENTARY ON PREVENTION A POSSIBLE DRUG–DRUG INTERACTION: IS CONCURRENT ADMINISTRATION OF ORLISTAT AND PIOGLITAZONE INCREASE THE RISK OF DURG?INDUCED HEPATOTOXICITY?,” INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, vol. 6, no. 2, pp. 0–0, 2015, [Online]. Available: https://sid.ir/paper/316275/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops